Literature DB >> 15533807

Comparison of inverse planning simulated annealing and geometrical optimization for prostate high-dose-rate brachytherapy.

I-Chow J Hsu1, Etienne Lessard, Vivian Weinberg, Jean Pouliot.   

Abstract

PURPOSE: An inverse planning simulated annealing (IPSA) algorithm for optimization of high-dose-rate (HDR) brachytherapy has been previously described. In this study, IPSA is compared with geometrical optimization (GO) for prostate brachytherapy. METHODS AND MATERIALS: Using CT data collected from 10 patients, treatment plans were prepared using GO and IPSA. The clinical target volume (CTV) and critical organs (CO) including bladder, rectum, and urethra were contoured using Plato Version 14.2.1 (Nucletron Corp., Veenendaal, The Netherlands). Implant catheters were digitized using the CT planning system. All dwell positions outside of the CTV were turned off. Two optimized plans were generated for each implant using GO and IPSA. The same set of dose constraints were used for all inverse planning calculations and no manual adjustment of the dwell weight was used. Two prescription methods were used. Using the first method, coverage was prioritized: the prescription dose was normalized to the isodose volume that covers 98% of the CTV (V100 = 98% of CTV). The dose volume histograms (DVH) of CO were generated for comparison. Using the second method, sparing was prioritized: the prescription dose was normalized such that no urethra volume received 150% of the prescription dose (V150-urethra = 0 cc). The DVH of CTV and CO were generated, and the homogeneity index (HI) and conformal index (COIN) were calculated for comparison and compared using the Wilcoxon matched-pairs test.
RESULTS: Using the coverage-prioritized method, the difference in V80-bladder dose was not statistically significant (p = 0.09; median: IPSA = 0.62 cc, GO = 1.05 cc). The V80-rectum ranged from 0.20-4.8 cc, and 0.05-1.4 cc using GO and IPSA, respectively. IPSA's V80-rectum was significantly lower (p = 0.005; median: IPSA=0.38 cc, GO = 1.31 cc). V150-urethra ranged from 0.02-0.75 cc and 0.0-0.01 cc using GO and IPSA, respectively. The V150-urethra was significantly lower using IPSA (p = 0.005; median: IPSA = 0.00 cc, GO = 0.33 cc). Using the sparing prioritized method, the V100-prostate ranged from 30-97% and 95-100% using GO and IPSA, respectively. This difference was statistically significant (p = 0.008). The HI and COIN were statistically higher using IPSA (p = 0.005).
CONCLUSION: Anatomy-based inverse optimization using IPSA is superior to dwell-position-based optimization using GO as it: (1) Improves target coverage and conformality while sparing normal structures, (2) Improves dose homogeneity within the target, and (3) Minimizes volume of non-contoured normal tissue irradiated. Routine application of three-dimensional brachytherapy planning and anatomy-based inverse dwell time optimization is recommended.

Entities:  

Mesh:

Year:  2004        PMID: 15533807     DOI: 10.1016/j.brachy.2004.05.007

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  15 in total

1.  Evolution in brachytherapy.

Authors:  Hugo Marsiglia; Enrique Chajon
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

2.  Comparison of manual and inverse optimisation techniques in high dose rate intracavitary brachytherapy of cervical cancer: A dosimetric study.

Authors:  Ram Abhinav Kannan; Janaki Manur Gururajachar; Arul Ponni; Kirthi Koushik; Mohan Kumar; Ram Charith Alva; Ritika Harjani; Arvind Murthy
Journal:  Rep Pract Oncol Radiother       Date:  2015-06-26

3.  Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI.

Authors:  Yongbok Kim; I-Chow J Hsu; Etienne Lessard; John Kurhanewicz; Susan Moyher Noworolski; Jean Pouliot
Journal:  Radiother Oncol       Date:  2008-02-20       Impact factor: 6.280

4.  Is there a subset of patients with recurrent cancer in the vagina who are not candidates for interstitial brachytherapy that can be treated with multichannel vaginal brachytherapy using graphic optimization?

Authors:  Deepinder P Singh; Kevin C Bylund; Ahmad Matloubieh; Ali Mazloom; Alexander Gray; Ravinder Sidhu; Lucille Barrette; Yuhchyau Chen
Journal:  J Contemp Brachytherapy       Date:  2015-04-28

5.  Dose error from deviation of dwell time and source position for high dose-rate 192Ir in remote afterloading system.

Authors:  Hiroyuki Okamoto; Ako Aikawa; Akihisa Wakita; Kotaro Yoshio; Naoya Murakami; Satoshi Nakamura; Minoru Hamada; Yoshihisa Abe; Jun Itami
Journal:  J Radiat Res       Date:  2014-02-23       Impact factor: 2.724

6.  Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.

Authors:  Shoichi Fukuda; Yuji Seo; Hiroya Shiomi; Yuji Yamada; Toshiyuki Ogata; Masahiro Morimoto; Koji Konishi; Yasuo Yoshioka; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2014-06-23       Impact factor: 2.724

7.  Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost.

Authors:  Adam Chicheł; Marek Kanikowski; Janusz Skowronek; Magdalena Dymnicka; Tomasz Piotrowski
Journal:  J Contemp Brachytherapy       Date:  2009-03-23

8.  Evaluation of hybrid inverse planning and optimization (HIPO) algorithm for optimization in real-time, high-dose-rate (HDR) brachytherapy for prostate.

Authors:  Shyam Pokharel; Suresh Rana; Joseph Blikenstaff; Amir Sadeghi; Bradley Prestidge
Journal:  J Appl Clin Med Phys       Date:  2013-07-08       Impact factor: 2.102

9.  Inverse planning for combination of intracavitary and interstitial brachytherapy for locally advanced cervical cancer.

Authors:  Kotaro Yoshio; Naoya Murakami; Madoka Morota; Ken Harada; Mayuka Kitaguchi; Kentaro Yamagishi; Shuhei Sekii; Kana Takahashi; Koji Inaba; Hiroshi Mayahara; Yoshinori Ito; Minako Sumi; Susumu Kanazawa; Jun Itami
Journal:  J Radiat Res       Date:  2013-05-31       Impact factor: 2.724

10.  Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.

Authors:  Christopher H Chapman; Steve E Braunstein; Jean Pouliot; Susan M Noworolski; Vivian Weinberg; Adam Cunha; John Kurhanewicz; Alexander R Gottschalk; Mack Iii Roach; I-Chow Hsu
Journal:  J Contemp Brachytherapy       Date:  2018-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.